COSCIENS Biopharma Inc. (CSCIF) revenue by segment
CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 20-F on Mar 25, 2026Score 1/30
$6.49+0.00 (0.00%)
Close on Oct 19, 2026Market cap $24.10MP/E –Yield –
Doanh thu theo bộ phận của COSCIENS Biopharma Inc.
Theo bộ phận kinh doanh
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active ingredient | $7.04M | $8.49M | $7.14M | $14.57M | – | – | – | – | – | – | 93.9% | -17.1% |
| Biopharmaceutical | $461.00K | $1.10M | – | – | – | – | – | – | – | – | 6.1% | -57.9% |
| Pharmaceutical | – | $1.10M | – | – | – | – | – | – | – | – | – | – |
| Denmark | – | – | $11.00K | $160.00K | $185.00K | $2.66M | $413.00K | – | – | – | – | – |
| Other | – | – | $48.00K | $3.00K | – | $19.00K | $45.00K | – | – | – | – | – |
| Ireland | – | – | $122.00K | $82.00K | – | $73.00K | $74.00K | – | – | – | – | – |
| Switzerland | – | – | $4.32M | $5.40M | $5.08M | $905.00K | – | – | – | – | – | – |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active ingredients | $7.04M | $8.49M | $7.14M | $14.57M | – | – | – | – | – | – | 93.9% | -17.1% |
| Biopharmaceutical | $461.00K | $1.10M | – | – | – | – | – | – | – | – | 6.1% | -57.9% |
| License fees | – | – | – | $1.70M | $1.67M | $911.00K | – | – | – | – | – | – |
| Royalties | – | – | – | $101.00K | $68.00K | $67.00K | – | – | – | – | – | – |
| Supply chain | – | – | – | $161.00K | $185.00K | $304.00K | – | – | – | – | – | – |
| Development services | – | – | – | $3.62M | $3.34M | – | – | – | – | – | – | – |
| Product sales | – | – | – | $57.00K | – | $2.37M | – | – | – | – | – | – |
| Novo Supply Agreements | – | – | – | – | $185.00K | $304.00K | $284.00K | – | – | – | – | – |
| Royalties Novo Amendement | – | – | – | – | $68.00K | $11.00K | – | – | – | – | – | – |
| License Novo Amendment | – | – | – | – | $1.67M | $843.00K | – | – | – | – | – | – |
| Development Services Novo Amendment | – | – | – | – | $3.34M | – | – | – | – | – | – | – |
| Royalties Strongbridge Agreement | – | – | – | – | – | $56.00K | $45.00K | – | – | – | – | – |
| License Strongbridge Agreement | – | – | – | – | – | $68.00K | $74.00K | – | – | – | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United states | $4.60M | $6.69M | $3.42M | $8.60M | – | – | – | $1.42M | $452.00K | $410.00K | 61.4% | -31.2% |
| Germany | $2.38M | $1.36M | $3.56M | $4.56M | – | – | – | – | – | – | 31.7% | +74.9% |
| United kingdom | $457.00K | $976.00K | – | – | – | – | – | – | – | – | 6.1% | -53.2% |
| Other | $59.00K | $260.00K | $164.00K | $83.00K | – | $19.00K | $45.00K | $0 | $3.00K | $51.00K | 0.8% | -77.3% |
| Columbia | – | $300.00K | – | – | – | – | – | – | – | – | – | – |
| China | – | – | – | $1.33M | – | – | – | $275.00K | $262.00K | $249.00K | – | – |
| Ireland | – | – | – | – | – | $73.00K | $74.00K | $24.91M | $0 | $0 | – | – |
| Denmark | – | – | – | – | – | $2.66M | $413.00K | – | – | – | – | – |
| Switzerland | – | – | – | – | – | $905.00K | – | – | – | – | – | – |
| Singapore | – | – | – | – | – | – | – | $0 | $0 | $101.00K | – | – |
| British Virgin Islands | – | – | – | – | – | – | – | $280.00K | $206.00K | $100.00K | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của COSCIENS Biopharma (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của COSCIENS Biopharma, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?